Abstract:Objective to investigate the clinical effect of Metoprolol combined with Trimetazidine on the treatment of coronary heart disease with heart failure.Methods A total of 100 patients with coronary heart disease and heart failure who admitted to Hongqi Hospital Affiliated to Mudanjiang Medical University from February 2017 to February 2018 were selected as the research objects and divided into the study group and the control group according to the random number table method,with 50 cases in each group.The observation group was treated with Metoprolol combined with Trimetazidine,the control group was treated with routine treatment.The cardiac function indexes and clinical effect were compared between the two groups..Results Before treatment,there were no statistically significant differences in heart rate (HR),left ventricular end systolic diameter (LVESD),left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) between the two groups (P>0.05).After treatment,the HR,LVESD,LVEDD in the study group were lower than those in the control group,the LVEF was higher than that in the control group,and the differences were statistically significant (P<0.05).After treatment,the HR,LVESD,LVEDD in the two groups were lower than those before treatment,the LVEF was higher than that before treatment,and the differences were statistically significant(P<0.05).The total effective rate of the study group (96.00%[48/50]) was higher than that of the control group (76.00%[38/50]),and the difference was statistically significant (P<0.05).Conclusion The treatment of Metoprolol combined with Trimetazidine in patients with coronary heart disease and heart failure can effectively improve the cardiac function of patients,and achieve very significant clinical effect,which is worthy of clinical promotion and application.
张凯;王欣慰;高雨秋. 美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果[J]. 中国当代医药, 2020, 27(36): 145-147.
ZHANG Kai ;WANG Xin-wei ;GAO Yu-qiu. Clinical effect of Metoprolol combined with Trimetazidine in the treatment of coronary heart disease with heart failure. 中国当代医药, 2020, 27(36): 145-147.